Replacing Cortisol Without a Second Hormone to Balance It
A single patient, confirmed ACTH deficiency after pituitary surgery, started on hydrocortisone with an intact renin-angiotensin system that makes her replacement genuinely different from primary adrenal insufficiency, not just a smaller version of it. The disagreement is how much smaller the dose should actually be.
P.J., a 58-year-old woman, retired two years ago from a career as a hospital pharmacist, which she mentions early in the visit — not to claim special insight, she says, but because she already knows enough to be nervous about getting this specific dose wrong in either direction. A 19mm nonfunctioning adenoma was resected eight weeks ago; a cosyntropin stimulation test performed four weeks post-op, timed to avoid the false-low results surgical stress can produce in the immediate postoperative window, confirmed central adrenal insufficiency with a peak cortisol of 12 mcg/dL, below the diagnostic threshold. Her aldosterone-renin axis, regulated independently through the renin-angiotensin system rather than through pituitary ACTH, is intact and normal — the specific fact that distinguishes her replacement needs from primary adrenal insufficiency, where the adrenal gland itself fails and both cortisol and aldosterone are lost together.
That distinction is not a minor technical footnote; it changes both what she needs and how her replacement gets monitored. She needs no mineralocorticoid replacement at all, since fludrocortisone exists to replace aldosterone specifically, and her aldosterone production is untouched by her pituitary disease. Her glucocorticoid dose itself is also a genuinely separate question from primary adrenal insufficiency's traditional 15-25mg daily hydrocortisone range: a growing body of clinical practice, reflecting a real shift in specialist opinion over the past decade, favors lower physiologic replacement — often 10-15mg daily in divided doses — specifically because central adrenal insufficiency patients retain some baseline cortisol production in most cases, unlike primary adrenal failure's complete loss, and because chronic mild glucocorticoid over-replacement carries its own real costs in bone density and metabolic health that accumulate silently over years of therapy nobody is actively titrating down. Her own baseline DEXA, already osteopenic before any glucocorticoid exposure at all, makes that accumulating cost less theoretical for her specifically than it would be in a patient starting from normal bone density.
Dosing cortisol without the axis that would tell you if you're overdoing it
I'd start her on the lower end of physiologic replacement — 10mg on waking, 5mg mid-afternoon — rather than the traditional 15-25mg range used historically and still common for primary adrenal insufficiency. Central adrenal insufficiency patients typically retain some residual cortisol production, unlike complete primary adrenal failure, and the lower-dose approach reflects a real, deliberate shift in practice over the past decade specifically to avoid the bone and metabolic cost of chronic mild over-replacement.
I agree with lower dosing as the target, but I'd be careful about starting there this early. She's eight weeks post-op, still in a window where surgical stress, incomplete recovery of any residual corticotroph function, and the general fragility of early replacement make me want a slightly more generous starting dose with a planned taper, rather than starting lean and hoping she doesn't have a rough week before we've established she tolerates it.
Her own history as a pharmacist cuts both ways here — she'll recognize under-replacement symptoms early, which argues for starting lean and trusting her to flag problems, but she's also going to be anxious about exactly this kind of judgment call, which argues for a plan that doesn't ask her to tolerate a rocky first few weeks unnecessarily.
That's a fair adjustment — start at 15mg total daily divided into a morning and early-afternoon dose, with an explicit taper toward 10-15mg over the following two months once she's clearly stable, rather than starting at the eventual target. Her bone density is already osteopenic, which is exactly the finding that makes the eventual lower target worth reaching, just not worth rushing into during an already unsettled recovery window.
Agreed: start hydrocortisone at 15mg total daily (10mg morning, 5mg early afternoon), with a planned taper toward 10-15mg total over the following two months once stability is confirmed — reaching the lower physiologic target appropriate to central adrenal insufficiency, but not immediately during an early post-operative window. No mineralocorticoid, given her intact aldosterone-renin axis. Full sick-day dosing education completed and documented before discharge from today's visit.
Both physicians agreed on the eventual target and the reasoning behind it; the disagreement was about the safest path to get there, resolved with an explicit taper rather than either starting lean immediately or defaulting to traditional higher dosing without a plan to reduce it.